Michael Wyatt to Neoplasms
This is a "connection" page, showing publications Michael Wyatt has written about Neoplasms.
Connection Strength
0.809
-
Advances in understanding the coupling of DNA base modifying enzymes to processes involving base excision repair. Adv Cancer Res. 2013; 119:63-106.
Score: 0.193
-
PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25.
Score: 0.172
-
Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol. 2008 Sep 15; 76(6):697-706.
Score: 0.141
-
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opin Drug Discov. 2023 01; 18(1):65-81.
Score: 0.096
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.083
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.055
-
Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014 Jul; 9(7):773-89.
Score: 0.053
-
Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. Sci Rep. 2017 02 22; 7:43023.
Score: 0.016